Friday, July 31, 2026

Depo-Provera Intake Leads a Firm-Concentrated Filing Day

Pharmaceutical and consumer-product claims concentrated the day’s heaviest MDL intake, led by Depo-Provera Products Liability Litigation (3140) with 24 complaints as McSweeney Langevin LLC filed nine and Anapol Weiss filed seven. Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (3060) followed with 23 filings divided between Morgan & Morgan PA and Singleton Schreiber LLP, with six each, while Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation (2738) added 17 matters driven by The Robinson Law Firm Prof Corp’s 14 and DV Injury Law’s two. Uber Technologies, Inc., Passenger Sexual Assault Litigation (3084) logged six new complaints, with Chaffin Luhana LLP and Peiffer Wolf each filing two, showing continued concentrated intake in the passenger-assault docket. Zantac Products Liability Litigation (2924) received four filings, all from Keller Postman LLC, reflecting transfer-in docket activity rather than renewed merits litigation. See the full filing feed and firm-level breakdowns here.

Spinal-Cord-Stimulation Study Sharpens Comparative Evidence Questions

A July 30 online publication found temporary spinal cord stimulation associated with fewer six-month postherpetic-neuralgia endpoints than dorsal-root-ganglion pulsed radiofrequency, creating a current comparative evidence record for Boston Scientific Spinal Cord Stimulator Product Liability (3181). In the matched cohort, the temporary-stimulation group had lower odds of the composite persistent-pain and sustained-medication endpoint, while procedure-related complication rates were similar between the approaches. The study does not identify a manufacturer, evaluate a challenged product, or establish defect or causation in any claimant’s case. Its litigation consequence lies in the sharper expert dispute over whether device-specific evidence can be separated from comparative treatment outcomes and patient-selection factors.

NEC Study Adds a Perinatal Variable to Causation Disputes

A July 29 online publication associated labor before delivery with lower adjusted odds of necrotizing enterocolitis among very-low-birth-weight infants, adding a fresh perinatal risk-stratification record for Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation (3026). The retrospective cohort found no difference in surgical NEC despite the association with lower overall NEC odds. The finding reinforces that NEC causation disputes turn on competing neonatal and perinatal pathways, not exposure evidence in isolation. Counsel will have to test whether labor history and related clinical circumstances affect individualized causation opinions in formula-feeding claims.